A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43% Market Closed
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note

AFT Pharmaceuticals Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AFT Pharmaceuticals Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
A
AFT Pharmaceuticals Ltd
NZX:AFT
Pre-Tax Income
NZ$17.2m
CAGR 3-Years
16%
CAGR 5-Years
8%
CAGR 10-Years
N/A
BLIS Technologies Ltd
NZX:BLT
Pre-Tax Income
NZ$696k
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cannasouth Ltd
NZX:CBD
Pre-Tax Income
-NZ$8.8m
CAGR 3-Years
-36%
CAGR 5-Years
-105%
CAGR 10-Years
N/A
Rua Bioscience Ltd
NZX:RUA
Pre-Tax Income
-NZ$13.7m
CAGR 3-Years
-30%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
G
Greenfern Industries Ltd
NZX:GFI
Pre-Tax Income
-NZ$1.6m
CAGR 3-Years
-8%
CAGR 5-Years
-83%
CAGR 10-Years
N/A
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A

See Also

What is AFT Pharmaceuticals Ltd's Pre-Tax Income?
Pre-Tax Income
17.2m NZD

Based on the financial report for Sep 30, 2024, AFT Pharmaceuticals Ltd's Pre-Tax Income amounts to 17.2m NZD.

What is AFT Pharmaceuticals Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
8%

Over the last year, the Pre-Tax Income growth was 10%. The average annual Pre-Tax Income growth rates for AFT Pharmaceuticals Ltd have been 16% over the past three years , 8% over the past five years .

Back to Top